MedPath

Clinical outcome and safety of neuromodulation for severe traumatic brain injury in terms of neurological recovery

Phase 2
Completed
Registration Number
TCTR20240325005
Lead Sponsor
Phramongkutklao hospital foundation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
68
Inclusion Criteria

1. all the adult patients with severe disability (GOS of 2 and 3) after trauma or stroke
2. Age more than 20 years
3. Patients have focal neurological deficits presenting with magnetic resonance imaging (MRI) brain or computed tomography (CT) head suggestive of MCA territory AIS presenting within 24 hour of symptom onset, National Institute of Health Stroke Scale (NIHSS) score of >4 and with a modified Rankin Scale (mRS) score of 0 or 1 before the stroke were included in this study.

Exclusion Criteria

Patients with brainstem strokes, transient ischemic attacks, brain tumor, demyelinating diseases, inflammatory diseases, craniotomies, hepatic failure, congestive heart failure, acute myocardial infarction, pregnancy and lactation, systemic malignancy, acute or chronic renal failure, and known allergy to above group of drugs.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
eurological outcome 6 months modified ranking score at 6 months
Secondary Outcome Measures
NameTimeMethod
disability improve ment 6 months NIHSS and BI scores at 6 months
© Copyright 2025. All Rights Reserved by MedPath